Advanced mutant receptor activator of nuclear factor kappa-Β ligand development with low affinity for osteoprotegerin

Yuria Jang; Yongjin Cho; Youngjong Ko; Yeonhee Moon; Chang-Moon Lee; Wonbong Lim

doi:10.1002/ctm2.70195

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70195 DOI: 10.1002/ctm2.70195

LETTER TO THE JOURNAL

Advanced mutant receptor activator of nuclear factor kappa-Β ligand development with low affinity for osteoprotegerin

Yuria Jang ¹^,²^,³
, Yongjin Cho ¹^,²
, Youngjong Ko ¹^,²^,³
, Yeonhee Moon ⁴
, Chang-Moon Lee ³^,⁵
, Wonbong Lim ¹^,²^,³^,⁶^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Yuria Jang, Yongjin Cho, Youngjong Ko, Yeonhee Moon, Chang-Moon Lee, Wonbong Lim. Advanced mutant receptor activator of nuclear factor kappa-Β ligand development with low affinity for osteoprotegerin. Clinical and Translational Medicine, 2025, 15(1): e70195 DOI:10.1002/ctm2.70195

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Li H, Xiao Z, Quarles LD, Li W. Osteoporosis: mechanism, molecular target and current status on drug development. Curr Med Chem. 2021;28:1489-1507.

[2]	Luo J, Yang Z, Ma Y, et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat Med. 2016;22:539-546.

[3]	Jin Y, Yang Y. LGR4: a new receptor for a stronger bone. Sci China Life Sci. 2016;59:735.

[4]	Ko YJ, Sohn HM, Jang Y, et al. A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor. Clin Transl Med. 2021;11:e368.

[5]	Jang Y, Lee H, Cho Y, et al. An LGR4 agonist activates the GSK 3beta pathway to inhibit RANK RANKL signaling during osteoclastogenesis in bone marrow derived macrophages. Int J Mol Med. 2024;53:10.

[6]	Jang Y, Sohn HM, Ko YJ, Hyun H, Lim W. Inhibition of RANKL-induced osteoclastogenesis by novel mutant RANKL. Int J Mol Sci. 2021;22:434.

[7]	Nelson CA, Warren JT, Wang MW, Teitelbaum SL, Fremont DH. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure. 2012;20:1971-1982.

[8]	Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S. RANKL/RANK/OPG pathway: a mechanism involved in exercise-induced bone remodeling. Biomed Res Int. 2020;2020:6910312.

[9]	Luan X, Lu Q, Jiang Y, et al. Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J Immunol. 2012;189:245-252.

[10]	Wang Y, Michiels T, Setroikromo R, van Merkerk R, Cool RH, Quax WJ. Creation of RANKL mutants with low affinity for decoy receptor OPG and their potential anti-fibrosis activity. FEBS J. 2019;286:3582-3593.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.